Developer docs
API playgroundTry for free, no card

Search company profiles

Tyligand Bioscience

Full company profile

uuid0009p9v

Namestring
Tyligand Bioscience
Legal namestring
Tyligand Bioscience
Websiteurl
tyligand.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Tyligand Bioscience is a privately held biotechnology company headquartered in Shanghai, China (3728 Jinke Rd, Building 1, West Wing), founded in 2018 with 11–50 employees. The company's stated focus is the discovery and development of small molecule therapeutics for cancer and autoimmune diseases, organized around an "efficient engine for small molecule innovation" that targets molecular mechanisms of carcinogenesis and tumor microenvironment characteristics. Its work is oriented toward regulating oncogene expression and signaling pathways, disrupting the tumor microenvironment, and restoring immune normalcy.

The company's lead clinical-stage asset is TSN1611, a KRAS G12D inhibitor being developed for KRAS G12D-mutated cancers, with non-small cell lung cancer as the primary indication. KRAS G12D is recognized as a historically difficult-to-drug oncogenic target, and TSN1611 has progressed to clinical development with data presented at the 2026 ASCO GI (Gastrointestinal Cancers Symposium) in January 2026 and at the 2026 ASCO Rapid Oral Abstract Session in May 2026. The company is led by CEO and co-founder Tony Zhang, with academic co-founder Zhong-Yin Zhang and president/co-founder Boyu Zhong completing the founding team.

Tyligand operates as a pre-commercial, pre-revenue biopharmaceutical company. Its business model centers on advancing small molecule candidates through preclinical and clinical development toward eventual regulatory approval and commercialization. To date, the company has secured capital through two funding rounds — a 2020 round led by Med-Fine Capital and a July 2023 round led by Ming Bioventures with participation from BOHE Angel Fund, CMS Capital, Calor Capital, Shengdi Investment, TaiKun Fund, and YF Capital — but no partnerships, licensing agreements, or commercial customers have been disclosed. Current external engagement is limited to scientific dissemination through oncology conference presentations and the company website.

Short descriptiontext

Tyligand Bioscience is a Shanghai-based, privately held biotechnology company developing small molecule therapeutics, with its lead clinical-stage asset TSN1611, a KRAS G12D inhibitor in development for non-small cell lung cancer and other KRAS G12D-mutated malignancies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDongguan, China
HQ citystring
Dongguan
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule oncology drugs, KRAS G12D inhibitors, cancer therapeutics development, targeted biopharmaceuticals, oncology drug discovery
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development and Commercialization
TypeOne Time License
Description

As a pre-revenue biotech company focused on cancer therapeutic development, Tyligand generates no current revenue. The company is advancing its small molecule pipeline through research, preclinical, and clinical stages toward potential future commercialization of innovative cancer drugs.

en.tyligand.com.cn
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tyligand Bioscience discovers and develops small molecule therapeutics for cancer and autoimmune diseases. Its lead clinical asset is TSN1611, a novel KRAS G12D inhibitor being investigated in KRAS G12D-mutated non-small cell lung cancer and other malignancies. The company operates a small molecule innovation engine focused on oncogene signaling and tumor microenvironment modulation.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Tyligand Bioscience is an oncology-focused biotech company developing small molecule cancer therapeutics. The company's core product is TSN1611, a KRAS G12D inhibitor currently in clinical development. The research pipeline focuses on molecular mechanisms of carcinogenesis and tumor microenvironment characteristics, targeting oncogene signaling pathways and immune restoration.

Product and service1 record
1TSN1611
CategoryOncology Therapeutics / Small Molecule Drug
Description

TSN1611 is a proprietary small molecule KRAS G12D inhibitor in clinical development for the treatment of KRAS G12D-mutated cancers, with an initial focus on non-small cell lung cancer. It is Tyligand's primary clinical-stage therapeutic candidate and is intended for oncology patients harboring the KRAS G12D mutation.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Revolution Medicines is developing RAS-targeted small molecule inhibitors including RMC-9805 (KRAS G12D), making it the most direct competitor to Tyligand's TSN1611 in the same target space, same modality, and same oncology indication.

TypeDirect peer
Description

Mirati developed MRTX1133, a clinical-stage KRAS G12D inhibitor, before being acquired by BMS; it represents the closest US-headquartered G12D competitor and a model for the BD/acquisition path Tyligand may pursue.

TypeDirect peer
Description

Erasca is a clinical-stage precision oncology biotech developing small molecule inhibitors against RAS/MAPK pathway targets; comparable to Tyligand in modality, stage, and oncology focus.

TypeDirect peer
Description

Relay Therapeutics develops precision oncology small molecule therapies leveraging a structure-based drug design platform — sharing Tyligand's small-molecule, target-validated oncology thesis with a differentiated motion-based discovery approach.

TypeDirect peer
Description

Tango is a clinical-stage small molecule oncology company targeting synthetic-lethal and oncogenic mutations; comparable to Tyligand in stage, modality, and precision-oncology focus.

TypeBroad incumbent
Description

Amgen pioneered the KRAS inhibitor space with Lumakras (sotorasib, G12C) and is investing in next-generation RAS inhibitors; a broad incumbent whose portfolio touches Tyligand's target class while operating across many therapeutic areas.

TypeBroad incumbent
Description

Genentech/Roche is a dominant oncology incumbent with active interest in KRAS and difficult-to-drug targets; representative of the large pharma partners that Tyligand may ultimately seek for co-development or commercialization.

8HUTCHMED
TypeRegional player
Description

HUTCHMED is a Hong Kong-headquartered clinical-stage oncology biotech with operations in China; a closely comparable China-based oncology peer in geography, stage, and commercialization aspirations.

TypeRegional player
Description

BeiGene is a leading China-founded oncology biotech with global commercialization footprint; relevant as a regional scale comparison and indicator of the pathway for Chinese oncology assets to reach global markets.

TypeRegional player
Description

InventisBio is a China-based precision oncology biotech developing targeted small molecule therapies; comparable in geography and small-molecule oncology focus, though specific oncology targets differ.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tyligand Bioscience

Oncology Biopharmaceuticalstyligand.com

Tyligand Bioscience is a Shanghai-based, privately held biotechnology company developing small molecule therapeutics, with its lead clinical-stage asset TSN1611, a KRAS G12D inhibitor in development for non-small cell lung cancer and other KRAS G12D-mutated malignancies.

What Tyligand Bioscience does

Tyligand Bioscience is a privately held biotechnology company headquartered in Shanghai, China (3728 Jinke Rd, Building 1, West Wing), founded in 2018 with 11–50 employees. The company's stated focus is the discovery and development of small molecule therapeutics for cancer and autoimmune diseases, organized around an "efficient engine for small molecule innovation" that targets molecular mechanisms of carcinogenesis and tumor microenvironment characteristics. Its work is oriented toward regulating oncogene expression and signaling pathways, disrupting the tumor microenvironment, and restoring immune normalcy.

The company's lead clinical-stage asset is TSN1611, a KRAS G12D inhibitor being developed for KRAS G12D-mutated cancers, with non-small cell lung cancer as the primary indication. KRAS G12D is recognized as a historically difficult-to-drug oncogenic target, and TSN1611 has progressed to clinical development with data presented at the 2026 ASCO GI (Gastrointestinal Cancers Symposium) in January 2026 and at the 2026 ASCO Rapid Oral Abstract Session in May 2026. The company is led by CEO and co-founder Tony Zhang, with academic co-founder Zhong-Yin Zhang and president/co-founder Boyu Zhong completing the founding team.

Tyligand operates as a pre-commercial, pre-revenue biopharmaceutical company. Its business model centers on advancing small molecule candidates through preclinical and clinical development toward eventual regulatory approval and commercialization. To date, the company has secured capital through two funding rounds — a 2020 round led by Med-Fine Capital and a July 2023 round led by Ming Bioventures with participation from BOHE Angel Fund, CMS Capital, Calor Capital, Shengdi Investment, TaiKun Fund, and YF Capital — but no partnerships, licensing agreements, or commercial customers have been disclosed. Current external engagement is limited to scientific dissemination through oncology conference presentations and the company website.

Tyligand Bioscience firmographics

Firmographics
Name
Tyligand Bioscience
Legal name
Tyligand Bioscience
Website
https://tyligand.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Tyligand Bioscience is a Shanghai-based, privately held biotechnology company developing small molecule therapeutics, with its lead clinical-stage asset TSN1611, a KRAS G12D inhibitor in development for non-small cell lung cancer and other KRAS G12D-mutated malignancies.
Ownership category
akta.pro rank

Tyligand Bioscience industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Small molecule oncology drugs
  • KRAS G12D inhibitors
  • Cancer therapeutics development
  • Targeted biopharmaceuticals
  • Oncology drug discovery

Where Tyligand Bioscience is headquartered

Location

Headquarters

HQ city
Dongguan
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Tyligand Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development and Commercialization: As a pre-revenue biotech company focused on cancer therapeutic development, Tyligand generates no current revenue. The company is advancing its small molecule pipeline through research, preclinical, and clinical stages toward potential future commercialization of innovative cancer drugs.

Go-to-market motion1 record

Marketing channels1 record

Tyligand Bioscience product offering

Product offering

Core offering

Tyligand Bioscience discovers and develops small molecule therapeutics for cancer and autoimmune diseases. Its lead clinical asset is TSN1611, a novel KRAS G12D inhibitor being investigated in KRAS G12D-mutated non-small cell lung cancer and other malignancies. The company operates a small molecule innovation engine focused on oncogene signaling and tumor microenvironment modulation.

Product overview

Tyligand Bioscience is an oncology-focused biotech company developing small molecule cancer therapeutics. The company's core product is TSN1611, a KRAS G12D inhibitor currently in clinical development. The research pipeline focuses on molecular mechanisms of carcinogenesis and tumor microenvironment characteristics, targeting oncogene signaling pathways and immune restoration.

Differentiator

Problem solved

Functional benefit

Products and services

  • TSN1611 TSN1611 is a proprietary small molecule KRAS G12D inhibitor in clinical development for the treatment of KRAS G12D-mutated cancers, with an initial focus on non-small cell lung cancer. It is Tyligand's primary clinical-stage therapeutic candidate and is intended for oncology patients harboring the KRAS G12D mutation.

Companies that use Tyligand Bioscience

Customer profile

Segments1 record

Ideal customer profiles1 record

Tyligand Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Tyligand Bioscience partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Tyligand Bioscience competitors and assessment

Company assessment

Direct peers

  • Revolution Medicines: Revolution Medicines is developing RAS-targeted small molecule inhibitors including RMC-9805 (KRAS G12D), making it the most direct competitor to Tyligand's TSN1611 in the same target space, same modality, and same oncology indication.
  • Mirati Therapeutics (Bristol Myers Squibb): Mirati developed MRTX1133, a clinical-stage KRAS G12D inhibitor, before being acquired by BMS; it represents the closest US-headquartered G12D competitor and a model for the BD/acquisition path Tyligand may pursue.
  • Erasca: Erasca is a clinical-stage precision oncology biotech developing small molecule inhibitors against RAS/MAPK pathway targets; comparable to Tyligand in modality, stage, and oncology focus.
  • Relay Therapeutics: Relay Therapeutics develops precision oncology small molecule therapies leveraging a structure-based drug design platform — sharing Tyligand's small-molecule, target-validated oncology thesis with a differentiated motion-based discovery approach.
  • Tango Therapeutics: Tango is a clinical-stage small molecule oncology company targeting synthetic-lethal and oncogenic mutations; comparable to Tyligand in stage, modality, and precision-oncology focus.

Broad incumbents

  • Amgen: Amgen pioneered the KRAS inhibitor space with Lumakras (sotorasib, G12C) and is investing in next-generation RAS inhibitors; a broad incumbent whose portfolio touches Tyligand's target class while operating across many therapeutic areas.
  • Genentech (Roche): Genentech/Roche is a dominant oncology incumbent with active interest in KRAS and difficult-to-drug targets; representative of the large pharma partners that Tyligand may ultimately seek for co-development or commercialization.

Regional players

  • HUTCHMED: HUTCHMED is a Hong Kong-headquartered clinical-stage oncology biotech with operations in China; a closely comparable China-based oncology peer in geography, stage, and commercialization aspirations.
  • BeiGene: BeiGene is a leading China-founded oncology biotech with global commercialization footprint; relevant as a regional scale comparison and indicator of the pathway for Chinese oncology assets to reach global markets.
  • InventisBio: InventisBio is a China-based precision oncology biotech developing targeted small molecule therapies; comparable in geography and small-molecule oncology focus, though specific oncology targets differ.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Tyligand Bioscience social profiles

Digital presence

Tyligand Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tyligand Bioscience leadership team

Management profile

Number of profiles

Profiles3 records

Tyligand Bioscience funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tyligand Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tyligand Bioscience

What does Tyligand Bioscience do?

Tyligand Bioscience discovers and develops small molecule therapeutics for cancer and autoimmune diseases. Its lead clinical asset is TSN1611, a novel KRAS G12D inhibitor being investigated in KRAS G12D-mutated non-small cell lung cancer and other malignancies. The company operates a small molecule innovation engine focused on oncogene signaling and tumor microenvironment modulation.

When was Tyligand Bioscience founded?

Tyligand Bioscience was founded in 2018. It employs 11 to 50 people.

Where is Tyligand Bioscience based?

Tyligand Bioscience is headquartered in Dongguan, China, in the Asia region.

How does Tyligand Bioscience make money?

One revenue line is on record: biopharmaceutical Development and Commercialization.

Who are Tyligand Bioscience's main competitors?

Direct peers on record are Revolution Medicines, Mirati Therapeutics (Bristol Myers Squibb), Erasca, Relay Therapeutics and Tango Therapeutics. Broad incumbents are Amgen and Genentech (Roche). Regional players are HUTCHMED, BeiGene and InventisBio.

Does Tyligand Bioscience have an API?

No public API is recorded for Tyligand Bioscience.

What industry is Tyligand Bioscience in?

Tyligand Bioscience's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals